Pharmacotherapeutic potential of bilobetin to combat chromium induced hepatotoxicity via regulating TLR-4, Nrf-2/Keap-1, JAK1/STAT3 and NF-κB pathway: A pharmacokinetic and molecular dynamic approach

Chromium (Cr) is one of the top-notch noxious heavy metals that is documented to exert deleterious effects on various body organs including the liver. Bilobetin (BLB) is a natural flavonoid which exhibits a wide range of medicinal properties. This trial was executed to investigate the pharmacotherapeutic potential of BLB to avert Cr instigated hepatotoxicity via modulating TLR4, JAK1/STAT3, Nrf-2/Keap-1 and NF-κB pathway. Our trial was executed on thirty-six male albino rats that were segregated into four equal groups including the control, Cr (10 mg/kg), Cr (10 mg/kg) + BLB (12 mg/kg) and BLB (12 mg/kg) alone treated group. Various biochemical parameters were assessed by using qRT-PCR, molecular docking, molecular dynamic simulation and histological approaches. Our results revealed that Cr administration significantly impaired the health of hepatic tissues by reducing the gene expression of Nrf-2 and its downregulating genes while promoting the levels of oxidative stress markers (ROS and MDA). Moreover, Cr administration upregulated the hepatic enzymes including ALT, GGT, AST, and ALP while concurrently decreasing the levels of total protein and albumin. Cr exposure also elevated the gene expression of pro-inflammatory cytokines including toll-like receptor 4 (TLR4), high mobility group box 1 (HMGB1) nuclear factor kappa B (NF-κB), Janus kinase 1 (JAK1), signal transducer and activator of transcription 3 (STAT3), tumor necrosis factor alpha (TNF-α), C-reactive proteins, interferon-gamma inducible protein-10 (IP-10), Interleukin beta-1(IL-1β), monocyte chemoattractant protein-1 (MCP-1), interleukin-6 (IL-6) and cyclooxygenase-2 (COX-2). Hepatic apoptosis was observed to be elevated following the Cr intoxication. Nonetheless, BLB treatment remarkably alleviated the hepatic damages via regulating the biochemical as well as histological profile of liver. Our findings are further endorsed by molecular docking analysis that demonstrated that BLB exhibit strong binding affinity to Keap-1 and STAT3 thus supporting its efficient hepatoprotective potential. BLB protected the hepatic tissues via regulating Cr induced impairments. These findings were confirmed by molecular docking and molecular dynamic simulation analysis. [Display omitted] •Chromium exposure dysregulated TLR4, JAK1/STAT3 pathway.•Chromium intoxication escalated the cellular oxidative stress.•Chromium administration promoted hepatic inflammation.•Bilobetin protected the hepatic tissues via regulating